A5011526018- CAR-T cell therapy research
- Advancements in Semiconductor Devices and Circuit Design
- Multiple Myeloma Research and Treatments
- Nanowire Synthesis and Applications
- Virus-based gene therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Integrated Circuits and Semiconductor Failure Analysis
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Hydrocarbon exploration and reservoir analysis
- CNS Lymphoma Diagnosis and Treatment
- Hydraulic Fracturing and Reservoir Analysis
- Monoclonal and Polyclonal Antibodies Research
- CO2 Sequestration and Geologic Interactions
Xuzhou Medical College
2021-2025
G protein-coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report the efficacy and safety of anti-GPRC5D chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory (R/R) MM.This phase Ⅱ, single-arm study enrolled (18-70 years) R/R MM. Lymphodepletion was performed before received 2 × 106/kg CAR cells. The primary end point proportion who achieved an overall response....
Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understanding of the characteristics and related risk factors CRS important effective management. total 142 patients acute lymphocyte leukemia (ALL), lymphoma, multiple myeloma (MM) received lymphodepletion...
Few studies have described chimeric antigen receptor (CAR) T-cell therapy for patients with B-cell acute lymphoblastic leukemia (B-ALL) central nervous system (CNSL) because of concerns regarding poor response and treatment-related neurotoxicity. Our study included 48 relapsed/refractory B-ALL CNSL to evaluate the efficacy safety CD19-specific CAR T cell–based therapy. The infusion resulted in an overall rate 87.5% (95% confidence interval [CI], 75.3-94.1) bone marrow (BM) disease remission...
Abstract Relapsed/refractory multiple myeloma patients with extramedullary disease (EMD) have unfavorable prognosis and lack effective therapy. Chimeric antigen receptor (CAR) T‐cell activities in EMD yet to be determined; how EMD‐specific microenvironment influences the clinical outcomes of CAR therapy remains great interest. In this prospective cohort study, histologically confirmed extra‐osseous were enrolled treated combined anti‐BCMA anti‐CD19 from May 2017 September 2023. Thirty‐one...
Abstract Few studies have reported the associations of granulocyte colony-stimulating factor (G-CSF) with cytokine release syndrome (CRS), neurotoxic events (NEs) and efficacy after chimeric antigen receptor (CAR) T-cell therapy for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). We present a retrospective study 67 patients R/R B-ALL who received anti-CD19 CAR therapy, 41 (61.2%) G-CSF (G-CSF group), while 26 (38.8%) did not (non-G-CSF group). Patients had similar...
Glucocorticoids (GCs) are often used to treat cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS). The effects of GCs on the efficacy CAR-T cell treatment in relapsed/refractory multiple myeloma (RRMM) have not been fully established. We evaluated impact clinical outcomes RRMM patients treated with cells.This study involved cells at our center between June 2017 December 2020. Patients were stratified into GC-used group (GC-group) non-GC-used (NGC-group)....
Abstract Relapsed/refractory (R/R) multiple myeloma (MM) patients with extramedullary disease (EMD) have grim prognoses and lack effective therapy. We conducted a comprehensive study of 31 R/R MM histologically confirmed extra-osseous EMD receiving anti-B-cell maturation antigen (BCMA) CAR T cell-based The safety/efficacy was assessed; immune microenvironment analyzed based on multiplex immunofluorescence pretherapy biopsy samples. Overall response occurred in 90.3% medullary 64.5% EMD....
Encouraging response has been achieved in relapsed/refractory (R/R) B-cell lymphoma treated by chimeric antigen receptor T (CAR-T) cells. The efficacy and safety of CAR-T cells central nervous system (CNSL) are still elusive. Here, we retrospectively analyzed 15 patients with R/R secondary CNSL receiving CD19-specific cell-based therapy. were infused CD19, CD19/CD20 or CD19/CD22 following a conditioning regimen cyclophosphamide fludarabine. overall rate was 73.3% (11/15), including 9 (60%)...